Cancer immunotherapy is a highly active area in translational medicine where the challenges and rewards of developing new drugs "from bench to bedside" become particularly visible. Here, we comment on both, the scientific and non-scientific hurdles of this translational process using the example of bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells, two closely related strategies for antibody-guided recruitment of T cells against cancer. Both exert impressive therapeutic activity and were recently approved for treatment of B-cell malignancies. We discuss how the efficacy of these auspicious therapeutic tools may be further improved, in particular against solid tumors, but we also address another critical issue: Since both approaches were already introduced in the 1980s, why did it take almost thirty years until they became clinically available?

中文翻译：

---

翻译的挑战。

癌症免疫疗法是转化医学中一个非常活跃的领域，在该领域中，开发新药“从长椅到床头”的挑战和回报尤为明显。在这里，我们以双特异性抗体（bsAbs）和嵌合抗原受体（CAR）T细胞为例，对翻译过程的科学和非科学障碍进行评论，这是抗体指导的针对T细胞针对T细胞的募集的两种密切相关的策略癌症。两者都具有令人印象深刻的治疗活性，最近被批准用于治疗B细胞恶性肿瘤。我们讨论了如何进一步提高这些吉祥的治疗工具的功效，尤其是针对实体瘤的功效，但我们也解决了另一个关键问题：由于这两种方法都是在1980年代引入的，